Summit Therapeutics Files 8-K on Key Agreements and Sales

TL;DR

Summit Therapeutics filed an 8-K on 10/21/25 covering material agreements, equity sales, and financial updates.

AI Summary

On October 21, 2025, Summit Therapeutics Inc. filed an 8-K report detailing several key events. The filing includes information on the entry into a material definitive agreement, unregistered sales of equity securities, and Regulation FD disclosures. It also covers financial statements and exhibits, with the report being filed as of October 22, 2025.

Why It Matters

This 8-K filing provides crucial updates on Summit Therapeutics' material agreements and equity transactions, which could impact investor understanding of the company's financial and strategic direction.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can indicate significant corporate actions and potential dilution or financing events.

Key Players & Entities

• Summit Therapeutics Inc. (company) — Registrant
• October 21, 2025 (date) — Date of Earliest Event Reported
• October 22, 2025 (date) — Date Filed
• 601 Brickell Key Drive, Suite 1000, Miami, FL 33131 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — nge on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq
• $18.74 — e "Common Stock"), at purchase price of $18.74 per Share, which was the closing price
• $500.0 million — roceeds to the Company of approximately $500.0 million. Robert W. Duggan, the Company's Co-C

Filing Documents

• d274712d8k.htm (8-K) — 35KB
• d274712dex101.htm (EX-10.1) — 167KB
• d274712dex102.htm (EX-10.2) — 76KB
• d274712dex991.htm (EX-99.1) — 19KB
• 0001193125-25-245790.txt ( ) — 491KB
• smmt-20251021.xsd (EX-101.SCH) — 3KB
• smmt-20251021_lab.xml (EX-101.LAB) — 18KB
• smmt-20251021_pre.xml (EX-101.PRE) — 11KB
• d274712d8k_htm.xml (XML) — 4KB

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "suggest," "target," "on track," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the expected closing date of the Private Placement. These and other risks are described in greater detail under the section titled "Risk Factors" contained in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company's other filings with the SEC. Any forward-looking statements that the company makes in this Current Report on Form 8-K are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this Current Report on Form 8-K. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: October 22, 2025 By: /s/ Manmeet Soni Chief Operating Officer, Chief Financial Off

View Full Filing

View this 8-K filing on SEC EDGAR